Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers.

Paik PK, Kim RK, Ahn L, Plodkowski AJ, Ni A, Donoghue MTA, Jonsson P, Villalona-Calero M, Ng K, McFarland D, Fiore JJ, Iqbal A, Eng J, Kris MG, Rudin CM.

Clin Cancer Res. 2020 Jan 9. pii: clincanres.3060.2019. doi: 10.1158/1078-0432.CCR-19-3060. [Epub ahead of print]

PMID:
31919132
2.

SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.

Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, Sauter JL, Kezlarian B, Jungbluth A, Desmeules P, Beras A, Bishop JA, Plodkowski AJ, Gounder MM, Schoenfeld AJ, Namakydoust A, Li BT, Rudin CM, Riely GJ, Jones DR, Ladanyi M, Travis WD.

J Thorac Oncol. 2019 Nov 18. pii: S1556-0864(19)33643-3. doi: 10.1016/j.jtho.2019.10.023. [Epub ahead of print]

3.

Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade.

Osorio JC, Arbour KC, Le DT, Durham JN, Plodkowski AJ, Halpenny DF, Ginsberg MS, Sawan P, Crompton JG, Yu HA, Namakydoust A, Nabet BY, Chaft JE, Riely GJ, Rizvi H, Diaz LA Jr, Hellmann MD.

J Clin Oncol. 2019 Dec 20;37(36):3546-3555. doi: 10.1200/JCO.19.00709. Epub 2019 Nov 1.

PMID:
31675272
4.

Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors.

Lin JJ, Schoenfeld AJ, Zhu VW, Yeap BY, Chin E, Rooney M, Plodkowski AJ, Digumarthy SR, Dagogo-Jack I, Gainor JF, Ou SI, Riely GJ, Shaw AT.

J Thorac Oncol. 2019 Oct 26. pii: S1556-0864(19)33573-7. doi: 10.1016/j.jtho.2019.10.014. [Epub ahead of print]

PMID:
31669591
5.

Prevalence of Occult Peribronchial N1 Nodal Metastasis in Peripheral Clinical N0 Small (≤2 cm) Non-Small Cell Lung Cancer.

Robinson EM, Ilonen IK, Tan KS, Plodkowski AJ, Bott M, Bains MS, Adusumilli PS, Park BJ, Rusch VW, Jones DR, Huang J.

Ann Thorac Surg. 2020 Jan;109(1):270-276. doi: 10.1016/j.athoracsur.2019.07.037. Epub 2019 Aug 31.

PMID:
31479639
6.

Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer.

Suzawa K, Offin M, Schoenfeld AJ, Plodkowski AJ, Odintsov I, Lu D, Lockwood WW, Arcila ME, Rudin CM, Drilon A, Yu HA, Riely GJ, Somwar R, Ladanyi M.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00011. Epub 2019 May 10. No abstract available.

7.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.

Hastings K, Yu HA, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K.

Ann Oncol. 2019 Aug 1;30(8):1311-1320. doi: 10.1093/annonc/mdz141.

8.

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.

Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT, Rudin CM, Kris MG, Rosen NX, Yu HA, Riely GJ, Arcila ME, Somwar R, Ladanyi M.

J Thorac Oncol. 2019 May;14(5):802-815. doi: 10.1016/j.jtho.2018.12.038. Epub 2019 Mar 1.

PMID:
30831205
9.

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.

Lai WV, Lebas L, Barnes TA, Milia J, Ni A, Gautschi O, Peters S, Ferrara R, Plodkowski AJ, Kavanagh J, Sabari JK, Clarke SJ, Pavlakis N, Drilon A, Rudin CM, Arcila ME, Leighl NB, Shepherd FA, Kris MG, Mazières J, Li BT.

Eur J Cancer. 2019 Mar;109:28-35. doi: 10.1016/j.ejca.2018.11.030. Epub 2019 Jan 24.

PMID:
30685684
10.

Rate and risk factors for AKI after CT scans in a cancer cohort
.

Latcha S, Plodkowski AJ, Zheng J, Jaimes EA.

Clin Nephrol. 2019 Mar;91(3):147-154. doi: 10.5414/CN109591.

11.

Dual-Energy CT Angiography for Detection of Pulmonary Emboli: Incremental Benefit of Iodine Maps.

Weidman EK, Plodkowski AJ, Halpenny DF, Hayes SA, Perez-Johnston R, Zheng J, Moskowitz C, Ginsberg MS.

Radiology. 2018 Nov;289(2):546-553. doi: 10.1148/radiol.2018180594. Epub 2018 Sep 11.

12.

Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition.

von Reibnitz D, Chaft JE, Wu AJ, Samstein R, Hellmann MD, Plodkowski AJ, Zhang Z, Shi W, Dick-Godfrey R, Panchoo KH, Barker CA, Rimner A.

Adv Radiat Oncol. 2018 May 9;3(3):391-398. doi: 10.1016/j.adro.2018.05.001. eCollection 2018 Jul-Sep.

13.

Computed tomography-derived assessments of regional muscle volume: Validating their use as predictors of whole body muscle volume in cancer patients.

Halpenny DF, Goncalves M, Schwitzer E, Golia Pernicka J, Jackson J, Gandelman S, Moskowitz CS, Postow M, Mourtzakis M, Caan B, Jones LW, Plodkowski AJ.

Br J Radiol. 2018 Dec;91(1092):20180451. doi: 10.1259/bjr.20180451. Epub 2018 Oct 3.

14.

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A.

Ann Oncol. 2018 Oct 1;29(10):2085-2091. doi: 10.1093/annonc/mdy334.

15.

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD.

J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20.

PMID:
30125216
16.

Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.

Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, Wilkins O, Panora E, Halpenny DF, Long NM, Kris MG, Rudin CM, Chaft JE, Hellmann MD.

Cancer Immunol Res. 2018 Sep;6(9):1093-1099. doi: 10.1158/2326-6066.CIR-17-0755. Epub 2018 Jul 10.

17.

Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.

Lin JJ, Zhu VW, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ou SI, Shaw AT, Riely GJ.

J Thorac Oncol. 2018 Oct;13(10):1530-1538. doi: 10.1016/j.jtho.2018.06.005. Epub 2018 Jun 20.

18.

CT features of HER2-mutant lung adenocarcinomas.

Sawan P, Plodkowski AJ, Li AE, Li BT, Drilon A, Capanu M, Ginsberg MS.

Clin Imaging. 2018 Sep - Oct;51:279-283. doi: 10.1016/j.clinimag.2018.05.028. Epub 2018 Jun 7. Review.

19.

Type A thymoma presenting with bone metastasis.

Montecalvo J, Chang J, Rekhtman N, Antonescu CR, Bains MS, Fabbri N, Plodkowski AJ, Riely GJ, Travis WD, Sauter JL.

Histopathology. 2018 Oct;73(4):701-703. doi: 10.1111/his.13662. Epub 2018 Jul 8. No abstract available.

PMID:
29855070
20.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

21.

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.

Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B.

Ann Oncol. 2018 Jun 1;29(6):1437-1444. doi: 10.1093/annonc/mdy103.

22.

Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?

Escalon JG, Harrington KA, Plodkowski AJ, Zheng J, Capanu M, Zauderer MG, Rusch VW, Ginsberg MS.

J Comput Assist Tomogr. 2018 Jul/Aug;42(4):601-606. doi: 10.1097/RCT.0000000000000727.

23.

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.

Drilon A, Somwar R, Mangatt BP, Edgren H, Desmeules P, Ruusulehto A, Smith RS, Delasos L, Vojnic M, Plodkowski AJ, Sabari J, Ng K, Montecalvo J, Chang J, Tai H, Lockwood WW, Martinez V, Riely GJ, Rudin CM, Kris MG, Arcila ME, Matheny C, Benayed R, Rekhtman N, Ladanyi M, Ganji G.

Cancer Discov. 2018 Jun;8(6):686-695. doi: 10.1158/2159-8290.CD-17-1004. Epub 2018 Apr 2.

24.

What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology?

Aherne EA, Plodkowski AJ, Montecalvo J, Hayan S, Zheng J, Capanu M, Adusumilli PS, Travis WD, Ginsberg MS.

Lung Cancer. 2018 Apr;118:83-89. doi: 10.1016/j.lungcan.2018.01.013. Epub 2018 Feb 3.

25.

Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer.

Goncalves MD, Taylor S, Halpenny DF, Schwitzer E, Gandelman S, Jackson J, Lukose A, Plodkowski AJ, Tan KS, Dunphy M, Jones LW, Downey RJ.

Clin Radiol. 2018 May;73(5):505.e1-505.e8. doi: 10.1016/j.crad.2017.12.004. Epub 2018 Jan 6.

26.

Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer.

Chan AT, Plodkowski AJ, Pun SC, Lakhman Y, Halpenny DF, Kim J, Goldburg SR, Matasar MJ, Moskowitz CS, Gupta D, Steingart R, Weinsaft JW.

J Cardiovasc Magn Reson. 2017 Oct 12;19(1):76. doi: 10.1186/s12968-017-0390-2.

27.

Lung Cancer: Postoperative Imaging and Complications.

de Groot PM, Shroff GS, Carter BW, Godoy MCB, Plodkowski AJ, P Ko J, Munden RF.

J Thorac Imaging. 2017 Sep;32(5):276-287. doi: 10.1097/RTI.0000000000000292. Review.

PMID:
28832414
28.

Investigation of patterns of nodal metastases in BRAF mutant lung cancer.

McEvoy SH, Halpenny DF, Viteri-Jusué A, Hayes SA, Plodkowski AJ, Riely GJ, Ginsberg MS.

Lung Cancer. 2017 Jun;108:62-65. doi: 10.1016/j.lungcan.2017.02.024. Epub 2017 Mar 1.

29.

Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.

Jakubowski CD, Plodkowski AJ, Chang JC, Rekhtman N, Iqbal A, Paik PK, Yu HA.

Clin Lung Cancer. 2017 Jan;18(1):e81-e83. doi: 10.1016/j.cllc.2016.10.001. Epub 2016 Oct 26. No abstract available.

30.

Computed Tomographic Appearance of Organizing Pneumonia in an Oncologic Patient Population.

Long NM, Plodkowski AJ, Schor-Bardach R, Geyer AI, Zheng J, Moskowitz CS, Ginsberg MS.

J Comput Assist Tomogr. 2017 May/Jun;41(3):437-441. doi: 10.1097/RCT.0000000000000520.

31.

Can Discrepancies Between Coronary Computed Tomography Angiography and Cardiac Catheterization in High-Risk Patients be Overcome With Consensus Reading?

Steinberger S, Plodkowski AJ, Latson L, Levsky JM, Zalta B, Godelman A, Cohen HW, Haramati LB.

J Comput Assist Tomogr. 2017 Jan;41(1):159-164. doi: 10.1097/RCT.0000000000000481.

PMID:
27560020
32.

Case report of malignant pulmonary parenchymal glomus tumor: imaging features and review of the literature.

Cunningham JD, Plodkowski AJ, Giri DD, Hwang S.

Clin Imaging. 2016 Jan-Feb;40(1):144-7. doi: 10.1016/j.clinimag.2015.09.017. Epub 2015 Sep 30. Review.

33.

From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?

Plodkowski AJ, Drilon A, Halpenny DF, O'Driscoll D, Blair D, Litvak AM, Zheng J, Moskowitz CS, Ginsberg MS.

Lung Cancer. 2015 Nov;90(2):321-5. doi: 10.1016/j.lungcan.2015.09.018. Epub 2015 Sep 21.

34.

Postoperative complications after thoracic surgery for lung cancer.

Rotman JA, Plodkowski AJ, Hayes SA, de Groot PM, Shepard JA, Munden RF, Ginsberg MS.

Clin Imaging. 2015 Sep-Oct;39(5):735-49. doi: 10.1016/j.clinimag.2015.05.013. Epub 2015 Jun 4. Review.

PMID:
26117564
35.

Imaging of thoracic cavity tumors.

Hayes SA, Plodkowski AJ, Ginsberg MS.

Surg Oncol Clin N Am. 2014 Oct;23(4):709-33. doi: 10.1016/j.soc.2014.06.005. Epub 2014 Aug 6. Review.

PMID:
25246047
36.

Preoperative computed tomography findings predict surgical resectability of thymoma.

Hayes SA, Huang J, Plodkowski AJ, Katzen J, Zheng J, Moskowitz CS, Ginsberg MS.

J Thorac Oncol. 2014 Jul;9(7):1023-30. doi: 10.1097/JTO.0000000000000204.

37.

Lamellated hyperintense synovitis: potential MR imaging sign of an infected knee arthroplasty.

Plodkowski AJ, Hayter CL, Miller TT, Nguyen JT, Potter HG.

Radiology. 2013 Jan;266(1):256-60. doi: 10.1148/radiol.12120042. Epub 2012 Oct 22.

PMID:
23091176

Supplemental Content

Loading ...
Support Center